• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers

  • — 19 Nov, 2013
Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to conventional therapies in the phase three TH3RESA study presented to the 2013 European Cancer Congress here.
Outcome data were announced from 602 women — selected for study because they had disease progression despite treatment with a taxane and at least two HER2-directed therapies (including trastuzumab and lapatinib) — who were randomized to treatment with either: a regimen of their physicians choice or T-DM1 — the drug combining trastuzumab with emtansine.
Professor Hans Wildiers MD PhD from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, described the combination drug as a ‘silver bullet’ — having a cancer-seeking arm linked to a cell-killing molecule. He said the data reaffirm the potential of T-DM1 as a treatment for HER2-positive metastatic breast cancer — demonstrating that the drug has the potential to be a new treatment paradigm for this group of patients who currently have few options.

You may also like...

  • Lung Cancer: Geriatric Assessment Before Concurrent Chemo-Radiotherapy Lung Cancer: Geriatric Assessment Before Concurrent Chemo-Radiotherapy 22 May, 2018
  • Dana Tsui Blood test for free tumour DNA could guide breast cancer therapy 3 Apr, 2013
  • ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 1 Jul, 2007
  • Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer 1 Oct, 2007
  • Previous story BREAST CANCER: Intraoperative radiotherapy at the time of lumpectomy is as effective as whole breast irradiation and associated with fewer non-cancer deaths
  • Next story The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Which Tasks Most Influence Pediatric PT Productivity,…
  • Home
  • Audio
  • Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.